ACP5 and osteoporosis: Therefore, promoting HO‐1 expression could be a potential therapeutic target for treating osteoporosis.[29] Our research suggests that DFO‐loaded PDAP NPs can enhance HO‐1 expression while suppressing osteoclast‐related gene expression such as Acp5, Nfatc1, and Ctsk, as well as osteoclast activity.